# US 2015/0147394 A1 · Pharmaceutical composition containing fimasartna and hydrochlorothiazide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147394 A1
- Document ID: US20150147394A1
- Status: Published application
- Kind: A1
- Application number: 14/411,871
- Filed: 2013-04-30
- Published: 2015-05-28
- Earliest claimed: 2012-06-28
- Assignees: Boryung Pharmaceutical Co., Ltd.
- Applicants: Boryung Pharmaceutical Co., Ltd.
- Inventors: Je Hak Kim; Kyung Wan Nam; Seo Hun Park; Ju Won Kim; Sang Yeop Kim
- Web page: https://patentgrep.com/patent/US20150147394A1

## CPC

- A61K 47/38: Cellulose; Derivatives thereof
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides: a pharmaceutical composition having a superior physical property since fimasartan and hydrochlorothiazide, which are main components of a combination preparation, have superior content uniformity; and a preparation method thereof.

## Claims

### Claim 1

A pharmaceutical composition comprising:
fimasartan, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof;
hydrochlorothiazide, a pharmaceutically acceptable salt hereof, a hydrate thereof, or a solvate thereof; and
a binder exhibiting a viscosity of 20 mPa·s to 1,000 mPa·s at 25° C.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the binder comprises at least one selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition has a relative standard deviation (RSD) of 4.0% or less in content uniformity test.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a tablet.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the tablet comprises an uncoated tablet and a coating layer.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the uncoated tablet has a hardness of 7 Kp or more.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is used for the treatment of hypertension.

### Claim 8

A method of preparing a pharmaceutical composition comprising fimasartan, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof and hydrochlorothiazide, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, the method comprising the steps of:
preparing a mixture comprising fimasartan, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof and hydrochlorothiazide, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof;
preparing granules by mixing the mixture with a binding solution in which a binder is dissolved to exhibit a viscosity of 20 mPa·s to 1,000 mPa·s at 25° C.; and
preparing an uncoated tablet containing the granules.

### Claim 9 (depends on 8)

The method of claim 8, further comprising the steps of:
preparing sized materials by sizing the granules;
preparing a final mixture by adding one or more additives to the sized materials; and
preparing the uncoated tablet by compressing the final mixture.

### Claim 10 (depends on 8)

The method of claim 8, wherein the binder comprises at least one selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.

### Claim 11 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition has a relative standard deviation (RSD) of 4.0% or less in content uniformity test.

### Claim 12 (depends on 8)

The method of claim 8, wherein the uncoated tablet has a hardness of 7 Kp or more.

### Claim 13 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition is used for the treatment of hypertension.

### Claim 14 (depends on 8)

A tablet prepared by the method of claim 8.

### Claim 15 (depends on 9)

A tablet prepared by the method of claim 9.

### Claim 16 (depends on 10)

A tablet prepared by the method of claim 10.

### Claim 17 (depends on 11)

A tablet prepared by the method of claim 11.

### Claim 18 (depends on 12)

A tablet prepared by the method of claim 12.

### Claim 19 (depends on 13)

A tablet prepared by the method of claim 13.
